Holen Sie sich die Stockscreener-App
77.58
4.89%
-3.99
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Spyre Therapeutics, Inc. (SYRE) stock price, news, quote and history - Yahoo Finance Australia
Spyre Therapeutics, Inc. (SYRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Dianthus Therapeutics, Inc. (DNTH) Stock Price, News, Quote & History - ca.finance.yahoo.com
Dianthus (NASDAQ: DNTH) officer set to sell 20,000 shares - Stock Titan
Dianthus Therapeutics at Cantor conference: pipeline gains speed By Investing.com - Investing.com South Africa
Dianthus Therapeutics at Cantor conference: pipeline gains speed By Investing.com - Investing.com Canada
DNTH: Claseprubart's strong clinical results and pipeline advances are driving rapid growth and expansion - TradingView
Dianthus Therapeutics at Cantor conference: pipeline gains speed By Investing.com - Investing.com UK
Dianthus: Hold, Based On Competitor C1s' CIDP Setback And Continued Claseprubart Advancement - Seeking Alpha
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen - Yahoo Finance
Dianthus Therapeutics R&D Head Randhawa Simrat Retains 4,000 Shares After Exercising and Selling Options - kalkinemedia.com
Dianthus gains new Buy from Citi on multi-blockbuster potential for lead drug - Seeking Alpha
Dianthus Therapeutics EVP Simrat Randhawa Executes Stock Options and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Officer at Dianthus (NASDAQ: DNTH) lines up 2026 stock sale after option exercise - Stock Titan
Dianthus Therapeutics to Participate in Three Investor Conferences During September - manilatimes.net
ZLAB Stock Price, Quote & News - Syfe
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case - Seeking Alpha
Dianthus (DNTH) Quarterly Figures: Profit Per Share Falls Below Its Benchmark for the Current Session - vinanet.vn
Bank of America Corp DE Trims Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Royal Bank of Canada Has $1.60 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Eagle Health Investments LP Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighStill a Buy? - MarketBeat
Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com Australia
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com Nigeria
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com South Africa
Dianthus Therapeutics director Simon Read sells $326,553 in stock - Investing.com
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com India
Dianthus Therapeutics director Simon Read sells $326,553 in stock - Investing.com
Dianthus (DNTH) Stock: Ends Down by 2.20% at $113.00 at the Close; Market Levels: the Supplied Trading Band Runs From $107.35 to $118.65 at the ClosePre-Earnings Momentum - vinanet.vn
Handelsbanken Fonder AB Invests $1.49 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics Director Simon Read Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - kalkinemedia.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TimesSquare Capital Management LLC Acquires Shares of 166,357 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
SCS Capital Management LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Stifel Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $133 - Moomoo
Walleye Capital LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics SVP Adam M. Veness Exercises 15,000 Stock Options at $18.17 Each - Kalkine Media
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com - Investing.com Canada
Dianthus Therapeutics stock hits 52-week high at 114.64 USD - Investing.com
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com - Investing.com UK
Sirenia Capital reveals 1.70M-share DNTH stake in Dianthus Therapeutics (DNTH) - Stock Titan
Dianthus Therapeutics (DNTH): Wellington group discloses 3.23M-share, 5.9% passive stake - Stock Titan
Dianthus therapeutics director Simon Read sells $304k in stock By Investing.com - Investing.com South Africa
0.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):